Biotech is booming, and that’s having an impact on deal terms. The author highlights a few observations from the Venture Financing Report of law firm Cooley LLP: money is flowing, valuations are up across the board, and deal terms are “looser” than they’ve ever been.
Biotech Venture Deal Terms Are More “Startup-Friendly” Than Ever
